Skip to main content
S&P 5007,633.98-0.30%DOW52,472.58-0.19%NASDAQ26,282.01-0.19%BTC$78,845.00+1.95%ETH$2,533.26+0.96%GOLD$4,354.50-1.23%OIL$101.64+1.59%
Smart Investors Daily
OK

NASDAQ · OKYO

OKYO Pharma Limited

Healthcare · Biotechnology

$1.40

Down-$0.02 (-1.07%)

Updated Sep 14, 2026, 4:40 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
79.92M
P/E ratio
-17.83
Dividend yield
0.00%
52-week range
$1.34 – $1.85
Volume
53.74K
Avg. volume
142.03K

Price performance

OKYO price history

1M range · 0 trading sessions · Daily adjusted prices

OKYO does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest OKYO news

The latest Smart Investors Daily articles mentioning OKYO.

Stock researchCompany · Overview

OKYO research

Overview

Company profile and research snapshot.

Company profile

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
OKYO recent ratings
DateFirmRatingTarget
Jul 13, 2026HC Wainwright & Co.Buy—
Feb 20, 2026Piper SandlerOverweight—
Dec 8, 2025B. Riley SecuritiesBuy—
Sep 23, 2025HC Wainwright & Co.Buy—
May 5, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal painLONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present at Ophthalmology Futures Forum and in

Yahoo · Sep 8, 2026

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Cantor Global Healthcare Conference being held September 9-11, 2026. Details of the event are as follows: Presenters: Flavio Mantelli, MD, PhD, Chief Medical Officer, Gary Jacob, PhD, Chief Development Of

Yahoo · Jul 28, 2026

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company’s ordinary shares on NASDAQ at $1.49 per share, bringing his total holding to 20,030 ordinary sh

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By